Pancreatic Cancer Research

ResearcherChina Medical UniversityActive in the last 2 years

Feng Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5868-7456; OpenAlex author ID A5100448816. Sources: OpenAlex.

Their work

Papers
5 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
9
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 5

  1. Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis. Last author DOI 10.1038/s42003-026-09538-6↗
  2. Gli1 promotes transforming growth factor-beta1- and epidermal growth factor-induced epithelial to mesenchymal transition in pancreatic cancer cells. Last author DOI 10.1016/j.surg.2015.03.016↗
  3. Overexpression of calreticulin contributes to the development and progression of pancreatic cancer. Last author DOI 10.1002/jcp.24519↗
  4. The clinicopathological significance and relationship of Gli1, MDM2 and p53 expression in resectable pancreatic cancer. Last author DOI 10.1111/his.12273↗
  5. Cooperation among Numb, MDM2 and p53 in the development and progression of pancreatic cancer. Last author DOI 10.1007/s00441-013-1679-6↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xiaodong Tan · 1 shared paper, 2026 · strength 0.32
  2. Tianqi Lu · 1 shared paper, 2026 · strength 0.32
  3. Zhongbo Zhang · 1 shared paper, 2026 · strength 0.32
  4. Qi Dong · 4 shared papers, 2013–2015 · strength 0.19
  5. Weiwei Sheng · 4 shared papers, 2013–2015 · strength 0.19
  6. Ming Dong · 4 shared papers, 2013–2015 · strength 0.19
  7. Qingfeng Liu · 3 shared papers, 2013–2015 · strength 0.15
  8. Jianping Zhou · 3 shared papers, 2013–2014 · strength 0.14
  9. Qingfeng Liu · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.